AB168337

Anti-P Glycoprotein antibody [EPR10364]

Name: Anti-P Glycoprotein antibody [EPR10364] (ab168337) | Abcam
Brand: Abcam Limited
SKU: AB168337
Price: 530 USD
Availability: InStock
Rating: 1 (2 reviews)

RabMAb
Recombinant
KO Validated
20ul selling size
What is this?

(2 Reviews)

(11 Publications)

Rabbit Recombinant Monoclonal P Glycoprotein antibody. Suitable for IHC-P, WB and reacts with Human, Mouse, Rat samples. Cited in 11 publications.

View Alternative Names

CD243, MDR1, PGY1, ABCB1, ATP-dependent translocase ABCB1, ATP-binding cassette sub-family B member 1, Multidrug resistance protein 1, P-glycoprotein 1, Phospholipid transporter ABCB1

7 Images

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

IHC-P

Lab

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human kidney tissue sections labeling P Glycoprotein with purified ab168337 at 1/100 dilution (14 μg/ml). Heat mediated antigen retrieval was performed using EDTA Buffer PH9. Hematoxylin was used to counter stain. ab97051 a Goat Anti-Rabbit IgG H&L (HRP) secondary antibody was used at 1/500 dilution. PBS instead of the primary antibody was used as the negative control.

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Immunohistochemical analysis of paraffin-embedded Human kidney tissue labeling P Glycoprotein with unpurified ab168337 at 1/50 dilution.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Immunohistochemical analysis of paraffin-embedded Human liver tissue labeling P Glycoprotein with unpurified ab168337 at 1/50 dilution.

Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

Lab

Western blot - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Lane 1 : Wild-type HAP1 cell lysate (20 μg)
Lane 2 : P glycoprotein knockout HAP1 cell lysate (20 μg)
Lane 3 : HeLa cell lysate (20 μg)
Lane 4 : HepG2 cell lysate (20 μg)

Lanes 1 - 4 : Merged signal (red and green). Green - ab168337 observed at 160 kDa. Red - loading control, ab8245, observed at 37 kDa.

ab168337 was shown to recognize P glycoprotein when P glycoprotein knockout samples were used, along with additional cross-reactive bands. Wild-type and P glycoprotein knockout samples were subjected to SDS-PAGE. ab168337 and ab8245 (loading control to GAPDH) were diluted 1/500 and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye^® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye^® 680RD) preadsorbed (ab216776) secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-P Glycoprotein antibody [EPR10364] (ab168337)

Predicted band size: 141 kDa

false

Lab

Western blot - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Blocking and diluting buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-P Glycoprotein antibody [EPR10364] (ab168337) at 1/2000 dilution

Lane 1:

HeLa (human cervix adenocarcinoma) whole cell lysate at 10 µg

Lane 2:

HepG2 (human hepatocellular carcinoma) whole cell lysate at 10 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 141 kDa

Observed band size: 180 kDa

false

Unknown

Western blot - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

All lanes:

Western blot - Anti-P Glycoprotein antibody [EPR10364] (ab168337) at 1/1000 dilution

Lane 1:

HeLa cell lysates at 10 µg

Lane 2:

293T cell lysates at 10 µg

Lane 3:

Human fetal brain lysates at 10 µg

Predicted band size: 141 kDa

false

Lab

Western blot - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Blocking and diluting buffer : 5% NFDM/TBST.

All lanes:

Western blot - Anti-P Glycoprotein antibody [EPR10364] (ab168337) at 1/2000 dilution

Lane 1:

Mouse brain lysate at 10 µg

Lane 2:

C6 (Rat glial tumor cell line) cell lysate at 10 µg

Secondary

All lanes:

Goat Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/1000 dilution

Predicted band size: 141 kDa

Observed band size: 180 kDa

false

Carrier free

Anti-P Glycoprotein antibody [EPR10364] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

EPR10364

Isotype

IgG

Carrier free

Reacts with

Mouse, Rat, Human

Applications

WB, IHC-P

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

P-glycoprotein 1 (also known as Multidrug resistance protein

has a predicted molecular weight of 141 kDa, however it has 3 potential glycosylation sites (N-linked) which may affect the migration of the protein. In our hands ab168337 detects a predominant protein band migrating in the region of 180-200 kDa and typically will demonstrate a smear on the membrane in the region of the 150 – 300 kDa due to the glycosylation profile of the protein. It may be necessary to optimise your cell or tissue lysis protocol to efficiently extract P-glycoprotein 1 as it is a multi-pass membrane protein. Abcam recommends not boiling the sample after lysis.

style

left-column

style

left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "1/100", "IHCP-species-notes": " Perform heat-mediated antigen retrieval before commencing with IHC staining protocol.", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/2000", "WB-species-notes": "For optimal detection Abcam recommends not boiling the sample after lysis." }, "Mouse": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/2000", "WB-species-notes": "For optimal detection Abcam recommends not boiling the sample after lysis." }, "Rat": { "IHCP-species-checked": "notRecommended", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/2000", "WB-species-notes": "For optimal detection Abcam recommends not boiling the sample after lysis." } } }

style

left-column

Product details

Patented technology
Our RabMAb^® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb^® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production

For more information, read more on recombinant antibodies.

style

left-column

Properties and storage information

Form

Liquid

Purification technique

Affinity purification Protein A

Storage buffer

Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

style

left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

P-glycoprotein also known as P-gp MDR1 transporter or ABCB1 is a well-characterized efflux transporter with a molecular mass of approximately 170 kDa. This protein is expressed in various normal tissues such as the liver intestine kidney blood-brain barrier and placenta. It is located on the cell membrane where it functions to expel a wide variety of substrates out of cells using energy derived from ATP hydrolysis. This capability of pumping out toxins and xenobiotics makes P-glycoprotein an important player in cellular detoxification.

Biological function summary

P-glycoprotein acts as a protective mechanism against toxic substances and drugs within the body. It is a member of the ATP-binding cassette (ABC) transporter family which is critical for their ability to transport molecules across membranes. P-glycoprotein is not typically part of a larger protein complex but can interact with other membrane proteins to facilitate its function. Its role in drug metabolism and excretion is vital for maintaining the balance and elimination of harmful substances.

Pathways

P-glycoprotein plays a significant role in the pharmacokinetics of drugs within the body. This transporter is involved in the multi-drug resistance (MDR) pathway which impacts the efficacy of chemotherapeutic agents. P-glycoprotein also interacts with other proteins like CYP3A4 which is involved in the metabolism of many drugs. These interactions affect the concentration and distribution of therapeutic agents contributing to the body's overall drug response.

P-glycoprotein is closely associated with multi-drug resistance in cancer where its overexpression can lead to reduced effectiveness of chemotherapy. It is also implicated in disorders of the central nervous system like epilepsy where it affects drug delivery to the brain. The protein has connections with CYP3A4 in these contexts where both together influence drug metabolism and efficacy complicating treatment regimens and therapeutic outcomes in these conditions.

style

left-column

style

left-column

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Visit the General protocols
Visit the Troubleshooting

style

left-column

Target data

Translocates drugs and phospholipids across the membrane (PubMed : 2897240, PubMed : 35970996, PubMed : 8898203, PubMed : 9038218, PubMed : 35507548). Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins (PubMed : 8898203). Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells (PubMed : 2897240, PubMed : 35970996, PubMed : 9038218).

See full target information ABCB1

style

left-column

Publications (11)

Recent publications for all applications. Explore the full list and refine your search

Thoracic cancer 16:e70079 PubMed40324967

2025

NAT10 Knockdown Improves Cisplatin Sensitivity in Non-Small Cell Lung Cancer by Inhibiting the TRIM44/PI3K/AKT Pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Qi Sun,Xiansong Yang,Ye Wang,Kejia Yang,Yuan Weng

Evidence-based complementary and alternative medicine : eCAM 2022:1897508 PubMed36276866

2022

Ginsenosides Rg1 and CK Control Temozolomide Resistance in Glioblastoma Cells by Modulating Cholesterol Efflux and Lipid Raft Distribution.

Applications

Unspecified application

Species

Unspecified reactive species

Runze Qiu,Jingjing Zhang,Chun Ge,Yue Zhong,Suo Liu,Qingquan Li,Jianjun Zou,Hongwei Fan,Yingbin Li

International journal of nanomedicine 17:3443-3456 PubMed35959279

2022

Investigation of the "Nose-to-Brain" Pathways in Intranasal HupA Nanoemulsions and Evaluation of Their in vivo Pharmacokinetics and Brain-Targeting Ability.

Applications

Unspecified application

Species

Unspecified reactive species

Yueyao Jiang,Yichuan Jiang,Zhiying Ding,Qian Yu

Journal of cellular and molecular medicine 25:7608-7620 PubMed34232553

2021

Long non-coding RNA LINC00607 silencing exerts antioncogenic effects on thyroid cancer through the CASP9 Promoter methylation.

Applications

Unspecified application

Species

Unspecified reactive species

Lanzhen Li,Zhongcheng Gao,Lei Zhao,Peiyou Ren,Hongyan Shen

Journal of translational medicine 18:439 PubMed33213473

2020

Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Razan Sheta,Magdalena Bachvarova,Marie Plante,Marie-Claude Renaud,Alexandra Sebastianelli,Jean Gregoire,Jamilet Miranda Navarro,Ricardo Bringas Perez,Jean-Yves Masson,Dimcho Bachvarov

Journal of controlled release : official journal o 321:132-144 PubMed32032656

2020

Nanomedicines blocking adaptive signals in cancer cells overcome tumor TKI resistance.

Applications

Unspecified application

Species

Unspecified reactive species

Hiroaki Kinoh,Hitoshi Shibasaki,Xueying Liu,Tatsuya Yamasoba,Horacio Cabral,Kazunori Kataoka

International journal of nanomedicine 14:9217-9234 PubMed31819426

2019

The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route.

Applications

Unspecified application

Species

Unspecified reactive species

Yueyao Jiang,Chenqi Liu,Wanchen Zhai,Ning Zhuang,Tengfei Han,Zhiying Ding

Journal of Cancer 10:2357-2368 PubMed31258739

2019

Co-delivery of Cyclopamine and Doxorubicin Mediated by Bovine Serum Albumin Nanoparticles Reverses Doxorubicin Resistance in Breast Cancer by Down-regulating P-glycoprotein Expression.

Applications

Unspecified application

Species

Unspecified reactive species

Yong-Lin Lu,Ya-Bin Ma,Chan Feng,Dong-Lei Zhu,Jie Liu,Lv Chen,Shu-Jing Liang,Chun-Yan Dong

Oncology letters 15:4649-4656 PubMed29541237

2018

Celecoxib enhances sensitivity to chemotherapy drugs of T-cell lymphoma.

Applications

Unspecified application

Species

Unspecified reactive species

Ming Ma,Xingxiao Yang,Lianmei Zhao,Xuexiao Wang,Lihua Liu,Wenjing Jiao,Yuanyuan Wei,Baoen Shan

Nature methods 12:1129-31 PubMed26524241

2015

Thermal proteome profiling monitors ligand interactions with cellular membrane proteins.

Applications

Unspecified application

Species

Unspecified reactive species

Friedrich B M Reinhard,Dirk Eberhard,Thilo Werner,Holger Franken,Dorothee Childs,Carola Doce,Maria Fälth Savitski,Wolfgang Huber,Marcus Bantscheff,Mikhail M Savitski,Gerard Drewes

View all publications

style

left-column

style

left-column

style

right-column

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.

For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com

Anti-P Glycoprotein antibody [EPR10364]

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Western blot - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Western blot - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Western blot - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Western blot - Anti-P Glycoprotein antibody [EPR10364] (AB168337)

Related conjugates and formulations (1)

Key facts

Host species

Clonality

Clone number

Isotype

Carrier free

Reacts with

Applications

Immunogen

Specificity

Alternative Products

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Complementary Products

Assay Kits

Secondary Antibodies

Primary Antibodies

Primary Antibodies

Primary Antibodies

Reactivity data

Product details

Properties and storage information

Form

Purification technique

Storage buffer

Shipped at conditions

Appropriate short-term storage duration

Appropriate short-term storage conditions

Appropriate long-term storage conditions

Aliquoting information

Storage information

Supplementary information

Biological function summary

Pathways

Product protocols

Target data

Publications (11)

Product promise